We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
By Angela Chen
Novartis AG will divest its nicotine replacement patch Habitrol, as mandated by the Federal Trade Commission, to go ahead with its consumer-health merger with GlaxoSmithKline.
As Novartis and GlaxoSmithKline are the only companies that market nicotine patches in the U.S., the FTC said the proposed joint venture would be anticompetitive and make it difficult for other companies to develop new patches.
Habitrol had U.S. sales of more than $58 million in 2013.
London-based GlaxoSmithKline and Swiss Novartis both manufacture consumer health-care products, including skin-care aids, cold-and-flu remedies, toothpaste and indigestion remedies.
The companies in April unveiled a set of complicated deals worth more than $20 billion that would create a new over-the-counter consumer-health business. The company, with sales of $11 billion, would be called GSK Consumer Healthcare. GlaxoSmithKline will control the business, with a 63.5% stake and seven of 11 board directors, and contribute its nicotine patch, Nicoderm CQ.
Write to Angela Chen at angela.chen@dowjones.com
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=GB0009252882
Access Investor Kit for GlaxoSmithKline Plc
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US37733W1053
Access Investor Kit for Novartis AG
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
